• 黑料社 and Clinigen signed exclusive long-term licensing and distribution agreement and commercial supply agreement for Xervyteg^庐 (MaaT013), its first in class treatment proposed for patients with acute Graft-versus-Host Disease
• In June 2025, the European Medicines Agency accepted for review the marketing authorization submission for this medicine
• 黑料社 will receive听a 鈧�10.5 million听upfront payment, further potential regulatory and sales milestones of up to听鈧�18 million, and royalties of a mid-thirties鈥� percentage on net sales. 黑料社 also entered into a supply agreement to provide Clinigen with finished medicine, at a pre-agreed price per unit
• If this medicine is approved with potential marketing authorization granted by mid-2026, it has the potential to be the first microbiota therapeutic approved in Europe, the first one in hemato-oncology globally and the first and only one in third-line aGvHD

Conference call and webcast to be held on July 3^rd, 2025, at 3:00PM CET/
9:00AM EDT/9:00PM CST –

Lyon, France, July 2nd, 2025 – 6:30pm CET 鈥� 黑料社 (EURONEXT: MAAT 鈥� the 鈥淐ompany鈥�), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies^TM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announces the signature of a license and commercial agreement with , a global specialty pharmaceutical services group and a leading European player in hospital distribution and market access, to streamline the pathway for ensuring access to this medicine across Europe¹. With this partnership, 黑料社 demonstrates its capability to supply products to pharmaceutical companies, including those specializing in rare diseases while ensuring scale-ups for commercial and extending its cash runway into January 2026.

Herv茅 Affagard, CEO and co-founder of 黑料社 says: 鈥淭his deal is a pivotal step in bridging 黑料社鈥檚 innovation with healthcare professionals who care for patients with aGvHD. Clinigen鈥檚 hemato-oncology expertise and leading European position in hospital distribution and market access make this team the ideal fit to bring this therapy to patients and we鈥檙e confident that this new relationship will maximize the full revenue generation potential of full revenue generation potential of Xervyteg^庐 (MaaT013). I look forward to working closely with the Clinigen team as we prepare for a successful launch.鈥�

Jerome Charton, CEO of Clinigen, says:听鈥�Following the EMA鈥檚 acceptance of 黑料社鈥檚 submission of an application for assessment for MaaT013 in June, we are very excited about this new relationship. This collaboration brings a novel technology to the forefront of rare disease and oncology care. We鈥檙e proud to play a leading role in ensuring access across Europe to this innovative therapy, and we look forward to working closely with 黑料社 as we prepare for potential launch.鈥�

Transaction Terms

Under the terms of the听agreement, 黑料社 will grant Clinigen exclusive European rights to distribute this medicine for the treatment of patients with aGvHD, if approved by the EMA. 黑料社 will receive an upfront payment of 鈧�10.5 million and additional eligible payments of up to 鈧�18 million depending on the achievement of pre-specified regulatory and sales milestones.听 黑料社 will also be eligible to receive royalty payments on net sales of a percentage in the mid-thirties and regular cash flow as per the supply agreement.

The hematology community has expressed interest in this medicine and this class of medicines to treat patients with aGvHD, as evidenced by the growing requests of Early Access Program between 2023 and 2024 (+75%). This program has been active in Europe since 2019. Under the terms of the agreement, Clinigen will take over this activity to meet the growing expectations of physicians while allowing 黑料社 to optimize its internal resources. This transition enhances 黑料社鈥檚 capacity to focus on clinical development, regulatory milestones, and industrial scale-up.

黑料社 management will host a conference call and webcast tomorrow Thursday,听July 3^nd, 2025, at听3:00pm CET/ 9:00am EDT/ 6:00am PT/ 9:00pm CST. Participants can also attend the conference by phone by dialing the following number: +33 1 78 42 94 76 + and using the PIN code 43 92 58

¹ Includes the following countries: European Union, Iceland, Norway, Liechtenstein and the United Kingdom

About Clinigen

Clinigen is a global, specialist pharmaceutical services company focused on providing ethical access to medicines. Its mission is to accelerate access to medicines for patients in every corner of the globe. The Group supports pharmaceutical and biotech companies across the medical product lifecycle, from clinical through to commercial and operates from sites in North America, Europe, Africa, and the Asia
Pacific. Clinigen has more than 1,100 employees across five continents in 15 countries and provides access in more than 130 countries every year.
For more information on Clinigen, please visit .

About 黑料社

黑料社 is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France.听As a pioneer, 黑料社 is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, 黑料社 develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. 黑料社 has been listed on Euronext Paris (ticker: MAAT) since 2021.

Forward-Looking statements

All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company鈥檚 control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as 鈥渢arget,鈥� 鈥渂elieve,鈥� 鈥渆xpect,鈥� 鈥渁im鈥�, 鈥渋ntend,鈥� 鈥渕ay,鈥� 鈥渁nticipate,鈥� 鈥渆stimate,鈥� 鈥減lan,鈥� 鈥減roject,鈥� 鈥渨ill,鈥� 鈥渃an have,鈥� 鈥渓ikely,鈥� 鈥渟hould,鈥� 鈥渨ould,鈥� 鈥渃ould鈥� and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company鈥檚 control that could cause the Company鈥檚 actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.

About acute Graft-versus-Host Disease

Acute Graft-versus-Host Disease occurs in patients within 100 days of undergoing a stem cell or bone marrow transplant, where the transplanted cells initiate an immune response and attack the transplant recipient鈥檚 organs, causing inflammation of the skin, liver and/or gastro-intestinal tract and leading to significant morbidity and mortality. GI involvement is associated with severe complications such as profound diarrhea, abdominal pain, intestinal bleeding, and death. These complications are often life-threatening, with increased mortality risk, due to the challenges of managing severe GI inflammation and the associated risks of infection, malnutrition, and organ failure. The standard first line therapy for treating aGvHD is the use of systemic steroids. If patients do not respond to steroids, they are considered Steroid Resistant (SR) and other agents can be administered. Currently the only agent approved for treating SR aGvHD after failure of steroid treatment is ruxolitinib, which is currently approved for this indication in USA and has received approval from the European Medicines Agency鈥檚 Committee for Human Medicinal Products (CHMP) on March 25, 2022.

About MaaT013 (Xervteg庐)

黑料社鈥檚 Microbiome Ecosystem Therapies (MET) are designed to leverage a full microbiome ecosystem to restore balance and maximize clinical benefits for patients with severe, treatment-induced dysbiosis in acute diseases. MaaT013 (Xervyteg庐) is a full-ecosystem, off-the-shelf, standardized, pooled-donors, enema Microbiome Ecosystem TherapyTM for acute, hospital use. It is characterized by a consistently high diversity and richness of microbial species and the presence of ButycoreTM (a group of bacterial species known to produce anti-inflammatory metabolites). MaaT013 (Xervyteg庐) aims to restore the symbiotic relationship between the patient鈥檚 functional gut microbiome and their immune system to correct the responsiveness and tolerance of immune functions and thus reduce steroid-resistant, gastrointestinal (GI)-aGvHD. MaaT013 (Xervyteg庐) has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

The post July 2nd, 2025: 黑料社 Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg庐 in acute Graft-versus Host Disease in Europe appeared first on 黑料社.

Lyon, France, September 4, 2024 鈥� 7:30am CET 鈥� 黑料社 (EURONEXT: MAAT 鈥� the 鈥淐ompany鈥�), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem Therapies^TM (MET) dedicated to improving survival outcomes for patients with cancer, announced that it will present two posters at the Society of Hematologic Oncology Annual Meeting taking place September 4-7, 2024, in Houston, Texas, USA. In addition, 黑料社 announced that Company management will participate in three investor conferences in September. Details are as follows:

Society of Hematologic Oncology Annual Meeting – Presentation

• Presentation Title 鈥� Poster MaaT013:听Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from Early Access Program in Europe – Poster Number:听CT-198
• Presentation Title 鈥� Poster MaaT033:听A Multicentre, Randomized, Double-Blinded, Phase 2b Study Evaluating The Efficacy And Safety Of Maat033, an Oral, Pooled Microbiome Ecosystem Therapy In Patients Undergoing Allogenic Hematopoietic Cell Transplantation to Improve Overall Survival: the PHOEBUS Study – Poster Number:听CT-200
• Session Date & Time: Wednesday, September 4, 2024, 6:15-7:30 PM CDT (7:15-8:30 PM EST)
• Location:听George R. Brown Convention Center, Houston, Texas, United States

Data included in both posters have been already presented at the 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in April 2024. The posters will be available on the Posters section of the 黑料社 website following the Congress.

Investor conferences

H.C. Wainwright 26th Annual Global Investment Conference – Presentation

• Date: September 9-11, 2024
• Location: New York, NY United States
• The presentation will be available on-demand through the H.C. Wainwright conference portal, starting Monday, September 9, 2024.

Lyon Pole Bourse Forum – Participation

• Date: September 24, 2024
• Location: Lyon, France

KBC Securities’ Life Sciences Conference – Participation

• Date: September 26, 2024
• Location: Brussels, Belgium

About 黑料社

黑料社, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, 黑料社 has launched, in March 2022, an open-label, single arm Phase 3 clinical trial in patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint庐, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company鈥檚 Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. 黑料社 benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. 黑料社 is listed on Euronext Paris (ticker: MAAT).

The post September 4, 2024: 黑料社 To Present and Participate in Investor and Medical Conferences in September appeared first on 黑料社.

Lyon, France, June 25^th 2024 鈥�6:00 pm CET 鈥� 黑料社 (EURONEXT: MAAT 鈥� the 鈥淐ompany鈥�), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem Therapies^TM (MET) dedicated to improving survival outcomes for patients with cancer, announces the initiation of coverage of its stock by Stifel, a US-based investment bank.

With a research report published today, Stifel initiated coverage of 黑料社 with a Buy recommendation and a Target Price of EUR 16.

Stifel is a US-based full-service investment bank offering securities brokerage, trading, research, underwriting, and corporate advisory services globally. Stifel is the largest global provider of small-cap equity research, with specialist life-sciences and medical technology expertise (Source: ).

This new coverage strengthens the visibility of 黑料社 among international and especially American institutional investors. It also adds to the ongoing coverage by the brokerage firms, Gilbert Dupont/ Groupe Soci茅t茅 G茅n茅rale, Kepler Cheuvreux, KBC Securities, Kempen and Portzamparc/Groupe BNP Paribas. They all have a Buy recommendation, with a consensus target price of EUR 15.20.

About 黑料社

黑料社, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, 黑料社 has launched, in March 2022, an open-label, single arm Phase 3 clinical trial in patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint庐, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company鈥檚 Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. 黑料社 benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. 黑料社 is listed on Euronext Paris (ticker: MAAT).

The post June 25, 2024: 黑料社 Announces Initiation of Coverage of its Stock by Stifel with a Buy Rating and a Target Price of EUR 16 appeared first on 黑料社.

Lyon, France, June 24^th 2024 鈥�6:00 pm CET 鈥� 黑料社 (EURONEXT: MAAT 鈥� the 鈥淐ompany鈥�), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem Therapies^TM (MET) dedicated to improving survival outcomes for patients with cancer, today announced the appointment of Gianfranco Pittari, M.D., Ph.D., as Chief Medical Officer. Dr. Pittari brings over 15 years of international experience in clinical research and drug development in hematology, oncology, and immunology. He will join the executive management team and oversee the clinical programs of the Company鈥檚 innovative microbiome-based drug candidates.

鈥淲e are very pleased to welcome Gianfranco to 黑料社. 听With his extensive experience leading clinical studies from early development through late-stage trials, he is a valuable addition to 黑料社鈥檚 team during this critical period of growth as our lead asset, MaaT013, nears Phase 3 trial completion,鈥� said Herv茅 Affagard, Chief Executive Officer and co-founder of 黑料社. 鈥淒r. Pittari鈥檚 international background strengthens our growing global team, reinforcing our expertise to excel in serving patients worldwide.鈥�

Dr. Pittari has extensive medical experience in drug development, particularly in oncology and hematology. His clinical work includes leading successful Phase I-III clinical trials at Celgene Corporation – Bristol Myers Squibb, where he was instrumental in the development of the first CAR T cell therapy for Multiple Myeloma (Abecma庐 – idecabtagene vicleucel), currently approved in both the US and the EU for use in earlier lines of treatment in patients with relapsed and refractory disease. Before joining 黑料社, he served as Executive Medical Director at Autolus, a clinical-stage biopharmaceutical company developing next-generation, programmed T Cell therapies treating cancer and autoimmune disease. He also held the position of Senior Consultant Hematology-BMT at the National Center for Cancer Care and Research in the State of Qatar, a leading international hub providing state-of-the-art clinical care, where he treated patients with hematological conditions and took part in multiple academic initiatives.

鈥淚 am inspired by 黑料社鈥檚 ambition and vision to serve physicians and bring innovative treatments to patients with high unmet needs in oncology,鈥� stated Dr. Pittari, Chief Medical Officer. 鈥淚 look forward to bringing my experience to support the team and contributing to the advancement of our microbiome drug candidates to help patients with cancer.鈥�

Dr. Pittari holds an M.D. degree from the University of Pavia, completed a Hematology fellowship at the University of Parma, and earned a Ph.D. in Immunology from Paris-Sud University. He has also conducted extensive academic research at both Gustave Roussy and Memorial Sloan-Kettering Cancer Center.

About 黑料社

黑料社, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, 黑料社 has launched, in March 2022, an open-label, single arm Phase 3 clinical trial in patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint庐, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company鈥檚 Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. 黑料社 benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. 黑料社 is listed on Euronext Paris (ticker: MAAT).

The post June 24, 2024: 黑料社 Appoints Gianfranco Pittari, M.D. Ph.D, as Chief Medical Officer appeared first on 黑料社.

Lyon, France, May 29 2024 鈥�6:00 pm CET 鈥� 黑料社 (EURONEXT: MAAT 鈥� the 鈥淐ompany鈥�), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem Therapies^TM (MET) dedicated to improving survival outcomes for patients with cancer, today presents the results of its Annual and Extraordinary General Meeting held on Tuesday, May 28, 2024 at 11:00 a.m. at the Company’s offices. The quorum reached by the shareholders present, representing, or voting remotely, was around 65% of voting shares.

Shareholders overwhelmingly approved most of the resolutions put forward by the Board of Directors by a majority of over 98% (only 31^st resolution was approved by almost 68%). In particular, they approved the renewal of the terms of office for current directors Mr. Jean-Marie Lefebvre, Mr. Karim Dabbagh, Mrs. Doroth茅e Burkel, Mrs. Nadia Kamal, Mr. Claude Bertrand, Mr. Herv茅 Affagard, Mr. Jean Volatier, Seventure Partners, and the appointment of a representative from Bpifrance Investissement as a director, along with the following resolutions:

• Approval of the financial statements for fiscal year 2023;
• The compensation policy for corporate officers (Chairman, Chief Executive Officer and Directors) and the compensation paid or awarded during 2023 fiscal year – details of the votes on the said resolution is available on the Company鈥檚 website here;
• Financial resolutions, notably delegations of authority to the Board of Directors to carry out capital increases in various situations;
• Delegation of authority to the Board of Directors to decide on any merger, demerger or partial contribution of assets (31st resolution).

Only one resolution was rejected:

• Delegation of authority to the Board of Directors to carry out a capital increase through the issue of shares or securities giving access to the capital, reserved for members of a company savings plan, with the cancellation of preferential subscription rights in their favor (38th resolution).

Following the Annual General Meeting, the Board of Directors renewed Mr. Karim Dabbagh as Chairman for the remainder of his term as director. Committee membership remains unchanged.

In accordance with the approval of resolutions 20 and 21, the Company also announces that the Board of Directors has decided to maintain the liquidity contract signed with Kepler Cheuvreux for the liquidity of the Company’s shares listed on Euronext Paris. Information on this contract is available in the Company’s Universal Registration Document.

The full minutes of the Annual General Meeting and the results of the votes, resolution by resolution, will be available shortly on the Company鈥檚 website www.maatpharma.com in the Investors/ General Meetings鈥� section.

About 黑料社

黑料社, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, 黑料社 has launched, in March 2022, an open-label, single arm Phase 3 clinical trial in patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint庐, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company鈥檚 Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. 黑料社 benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. 黑料社 is listed on Euronext Paris (ticker: MAAT).

The post May 29, 2024: 黑料社 Presents the Results of its Annual Ordinary and Extraordinary General Meeting appeared first on 黑料社.

THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES IN MAAT PHARMA OR ANY OTHER ENTITY IN ANY JURISDICTION.

黑料社 announces the successful completion of its Global Offering of 19.2 Million Euros

Lyon, France, May 15 2024 鈥�7.30 am CET 鈥� 黑料社 (EURONEXT: MAAT 鈥� the 鈥淐ompany鈥�), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem Therapies^TM (MET) dedicated to improving survival outcomes for patients with cancer,听 today announces the successful completion of its offering of 18.2 million euros, comprising a reserved offering of 2,161,250 new ordinary shares to institutional investors and a public offering of 112,454 new ordinary shares to retail investors via the PrimaryBid platform (the 鈥�Primary Offering鈥�), at a price of 鈧�8 per share (the 鈥�Offering Price鈥�).

The net proceeds from the Primary Offering, which are estimated to be approximately 鈧�17.3 million, will be used to fund the company鈥檚 R&D activities, covering completion of the Phase 3 trial for MaaT013 in Europe, including top-line results/primary endpoint in mid Q4 2024, continuing the pipeline development, including the initiation of Phase 3 trial activities for MaaT013 in the US and the broadening of the Phase 2b trial with MaaT033 across Europe and for working capital and other general corporate purposes, including repayment of current debts.

The Company estimates that, the total cash and cash equivalents as of March 31, 2024 of 鈧�18.2 million (unaudited), and the funds raised, will be able to finance its operations into early Q1 2025.

Concurrently with the Primary Offering, certain funds managed by Seventure Partners (together, the “Selling Shareholder“), have sold 125,000 existing shares, at the Offering Price, i.e. an amount of 鈧�1 million (the “Secondary Offering” and together with the Primary Offering, the “Global Offering“). These funds are currently in a divestment period and are progressively selling the shares they hold in the Company, but Seventure Partners will continue to support the development and growth of the Company and has committed to participate to the Reserved Offering through other funds.

Herv茅 Affagard, CEO and co-founder of 黑料社, commented: 鈥�I extend my gratitude to both our institutional and retail investors, as well as the financial commitment from the management team. 70% of new retail investors were previously non-shareholders, showcasing a strong influx of new support, with a total investment of 鈧�0.9 million.听Since our IPO in late 2021, 黑料社, leader in Microbiome/Oncology, has consistently met its objectives across various fronts. Today’s investment propels us further toward in harnessing the full potential of microbiome innovations. This raise will secure our upcoming completion of Phase 3, including primary endpoint results, for MaaT013 in treating refractory acute graft-versus-host disease and contribute to positioning us to further advance our therapeutic pipeline.鈥�

Main characteristics of the Global Offering

The Global Offering, for a total amount of 19.2听million euros, was carried out by the issue of 2,273,704 new ordinary shares, in the context of the Primary Offering through (i) a reserved offering, without pre-emptive subscription rights, for the benefit of specific categories of investors of 2,161,250 new ordinary shares were subscribed for by investors in the Reserved Offering for a total amount of approximately 17.3 million euros, in accordance with the 25^th resolution of the annual general meeting of June 19, 2023 (the 鈥�AGM鈥�) and pursuant to article L. 225-138 of the French Commercial Code (the 鈥�Reserved Offering鈥�), (ii) a public offering aimed at retail investors, via the PrimaryBid platform, of 112,454 new ordinary shares were subscribed for by investors in the Reserved Offering for a total amount of approximately 0.9 million euros, in accordance with the 23^rd resolution of the AGM and pursuant to article L. 225-136 of the French Commercial Code and article L. 411-2-1 1掳 of the French Monetary and Financial Code (the “PrimaryBid Offering“) and (iii) the sale of 125,000 existing ordinary shares representing 1 Million euros held by the Selling Shareholder to the same specific categories of investors defined in the Reserved Offering.

Upon completion of the Global Offering, the share capital of the Company will be composed of 13,897,143 ordinary shares with a par value of 鈧�0.10 each. The 2,273,704 newly issued ordinary shares, represent approximately 19.6% of the Company’s share capital, on a non-diluted basis, before completion of the Global Offering and 16.3% of the Company’s share capital, on a non-diluted basis, after completion of the Global Offering. By way of illustration, a shareholder holding 1% of the share capital prior to the Global Offering and which did not participate in the Global Offering will hold 0.84% after completion of the Global Offering.

The issue price of the new ordinary shares has been set at 鈧�8 per share, representing a discount of 14.3% to the closing price of the Company鈥檚 shares on the Euronext Paris regulated market at the time of the last trading session preceding its setting (i.e. May 14, 2024) in accordance with the decisions of the Company’s Chief Executive Officer pursuant to the sub-delegations of authority granted by the Company’s Board of Directors on May 14, 2024, in accordance with the 25^th, 23^rd and 27^th resolutions of the AGM.

To the best of the Company’s knowledge, the breakdown of shareholders before and after completion of the Global Offering is as follows:

Current shareholders Bpifrance Investissement, Biocodex and Seventure Partners which respectively held 15,51%, 10,62% and 22,31% of the Company鈥檚 share capital on a non-diluted basis, prior to the Global Offering, had pledged to subscribe 鈧�8 million, 鈧�5 million, and 鈧�1.3 million respectively in the Reserved Offering, subject to the Reserved Offering representing at least 鈧�17 million. The management of the Company has pledged to subscribe 鈧�100,000 in the Reserved Offering.

Members of the Company’s Board of Directors Mr. Herv茅 Affagard, Mr. Jean-Marie Lef猫vre for Biocodex and Mrs Isabelle de Cr茅moux for Seventure Partners subscribed to the Global Offering for a total amount of 鈧�6.3 million. It should be noted that none of the members of the Board of Directors having subscribed to the Global Offering took part in the vote on the decision setting its terms. These investors represent approximately 32% of the Global Offering.

Admission of new ordinary shares

Settlement-delivery of the new ordinary shares and their admission to trading on the regulated market of Euronext Paris are expected to occur on May 17, 2024. The new shares will be of the same class and fungible with the existing shares, will carry all rights attached to the shares, and will be admitted to trading on the Euronext Paris market under the same ISIN code FR0012634822 – MAAT.

Undertakings to retain shares and refrain from issuing shares

In connection with the Reserved Offering, participating Directors and certain existing shareholders namely, Bpifrance Investissement, Biocodex and Seventure Partners have respectively entered into a lock-up agreement with the Placement Agents for a period of 90 days from the settlement-delivery date of the Global Offering, subject to customary exceptions.

In connection with the Reserved Offering, the Company has undertaken to refrain from issuing shares for a period of 90 days from the settlement-delivery date of the Global Offering, subject to customary exceptions.

Financial Intermediaries

Stifel Europe AG (鈥�Stifel鈥�) is acting as Global Coordinator and Joint Bookrunner in connection with the Reserved Offering. Gilbert Dupont SNC, Groupe Soci茅t茅 G茅n茅rale, is acting as Joint Bookrunner in connection with the Reserved Offering. (together, the 鈥�Placement Agents鈥�). The Reserved Offering is subject to a placement agreement entered into between the Company and the Placement Agents dated May 14, 2024.

Within the framework of the PrimaryBid Offering, investors subscribed via the PrimaryBid partners mentioned on the PrimaryBid website (). The PrimaryBid Offering is subject to an engagement letter entered into between the Company and PrimaryBid and is not subject to a placement agreement.

Prospectus

Since the new ordinary shares issued over a period of听12 months, including in the context of the Reserved Offering represent less than听20听% of the number of securities already admitted to trading on the same regulated market, no listing prospectus would be subject to the approval of the French Financial Markets Authority (Autorit茅 des March茅s Financiers or the 鈥�AMF鈥�) pursuant to the Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (as amended, the 鈥�Prospectus Regulation鈥�).

This press release does not constitute a prospectus under Prospectus Regulation, or a public offering.

Risk factors

The public’s attention is drawn to the risk factors relating to the Company and its business, presented in chapter 3 of the universal registration document 2024 approved by the Autorit茅 des march茅s financiers on April 02, 2024, which is available free of charge on the Company’s website (www.maatpharma.com) and the website of the Autorit茅 des march茅s financiers (www.amf-france.org). The occurrence of any or all of these risks could have an adverse effect on the Company’s business, financial situation, results, development or prospects.

In addition, investors are invited to consider the following risks specific to the issue: (i) the market price of the Company’s shares could fluctuate and fall below the subscription price of the shares issued under the Global听 Offering, (ii) the volatility and liquidity of the Company’s shares could fluctuate significantly, (iii) sales of the Company’s shares could occur on the market and have an unfavorable impact on the Company’s share price, and (iv) the Company’s shareholders could suffer potentially significant dilution as a result of any future capital increases made necessary by the Company’s search for financing.

About 黑料社

黑料社, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, 黑料社 has launched, in March 2022, an open-label, single arm Phase 3 clinical trial in patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint庐, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company鈥檚 Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. 黑料社 benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. 黑料社 is listed on Euronext Paris (ticker: MAAT).

Forward-looking Statements

This press release includes forward looking statements. All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company鈥檚 control. These statements may include, without limitation, any statements preceded by, followed by or including words such as 鈥渢arget,鈥� 鈥渂elieve,鈥� 鈥渆xpect,鈥� 鈥渁im,鈥� 鈥渋ntend,鈥� 鈥渕ay,鈥� 鈥渁nticipate,鈥� 鈥渆stimate,鈥� 鈥減lan,鈥� 鈥減roject,鈥� 鈥渨ill,鈥� 鈥渃an have,鈥� 鈥渓ikely,鈥� 鈥渟hould,鈥� 鈥渨ould,鈥� 鈥渃ould鈥� and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company鈥檚 control that could cause the Company鈥檚 actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.

Disclaimer

This press release does not constitute an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of shares in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The distribution of this document may, in certain jurisdictions, be restricted by local legislations. Persons into whose possession this document comes are required to inform themselves about and to observe any such potential local restrictions.

This press release is an advertisement and not a prospectus within the meaning of the 鈥�Prospectus Regulation鈥�. Any decision to purchase shares must be made solely on the basis of publicly available information on the Company.

In France, the offer of 黑料社 shares described below will be made in the context of (i) a capital increase reserved to specified categories of beneficiaries, pursuant to article L. 225-138 of the French Commercial Code and applicable regulatory provisions and (ii) a public offering primarily intended to retail investors through the PrimaryBid platform, pursuant to article L. 225-136 of the French Commercial Code and article L.411-2-1, 1掳 of the French Monetary and Financial Code. Pursuant to article 211-3 of the General regulations of the AMF and articles 1(4) and 3 of the Prospectus Regulation, the offer of 黑料社 shares will not require the publication of a prospectus approved by the AMF.

With respect to Member States of the European Economic Area, no action has been taken or will be taken to permit a public offering of the securities referred to in this press release requiring the publication of a prospectus in any Member State. Therefore, such securities may not be and shall not be offered in any Member State other than in accordance with the exemptions of Article 1(4) of Prospectus Regulation or, otherwise, in cases not requiring the publication of a prospectus under Article 3 of the Prospectus Regulation and/or the applicable regulations in such Member State.

This press release and the information it contains are being distributed to and are only intended for persons who are (x) outside the United Kingdom or (y) in the United Kingdom and are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the 鈥�Order鈥�), (ii) high net worth entities and other such persons falling within Article 49(2)(a) to (d) of the Order (鈥渉igh net worth companies鈥�, 鈥渦nincorporated associations鈥�, etc.) or (iii) other persons to whom an invitation or inducement to participate in investment activity (within the meaning of Section 21 of the Financial Services and Market Act 2000) may otherwise lawfully be communicated or caused to be communicated (all such persons in (y)(i), (y)(ii) and (y)(iii) together being referred to as 鈥�Relevant Persons鈥�). Any invitation, offer or agreement to subscribe, purchase or otherwise acquire securities to which this press release relates will only be engaged with Relevant Persons. Any person who is not a Relevant Person should not act or rely on this press release or any of its contents.

This press release may not be distributed, directly or indirectly, in or into the United States. This press release and the information contained therein does not, and will not, constitute an offer of securities for sale, nor the solicitation of an offer to purchase, securities in the United States or any other jurisdiction where restrictions may apply. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the 鈥淪ecurities Act鈥�). The securities of 黑料社 have not been and will not be registered under the Securities Act, and 黑料社 does not intend to conduct a public offering in the United States.

The distribution of this press release may be subject to legal or regulatory restrictions in certain jurisdictions. Any person who comes into possession of this press release must inform him or herself of and comply with any such restrictions.

Any decision to subscribe for or purchase the shares or other securities of 黑料社 must be made solely based on information publicly available about 黑料社. Such information is not the responsibility of Stifel and Gilbert Dupont and has not been independently verified by Stifel and Gilbert Dupont.

The post May 15, 2024: 黑料社 announces the successful completion of its Global Offering of 19.2 Million Euros appeared first on 黑料社.

THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES IN MAAT PHARMA OR ANY OTHER ENTITY IN ANY JURISDICTION.

黑料社 Launches a Global Offering of a minimum of 18 Million Euros

Lyon, France, May 14 2024 鈥�5.45 pm CET 鈥� 黑料社 (EURONEXT: MAAT 鈥� the 鈥淐ompany鈥�), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem Therapies^TM (MET) dedicated to improving survival outcomes for patients with cancer, today announces the launch of an offering of approximately 18 million euros, comprising a reserved offering of new ordinary shares to categories of investors and a public offering of new ordinary shares to retail investors (via the PrimaryBid platform) (the 鈥�Primary Offering鈥�), and a sale of existing shares for 1 million euros, at a price of 鈧�8 per share (the 鈥�Offering Price鈥�).

黑料社 will use the net proceeds of the Primary Offering to fund the continued development of its Microbiome Ecosystem Therapies^TM, including:

• completion of the Phase 3 trial for MaaT013 in Europe, including top-line results/primary endpoint expected in mid-Q4 2024;
• refining the pipeline development, encompassing the initiation of Phase 3 trial activities for MaaT013 in the US and the broadening of the Phase 2b trial with MaaT033 across Europe; and
• working capital and other general corporate purposes, including repayment of current debts.

In the context of the Global Offering, the Company benefits from the long-term support of its historical shareholders Bpifrance Investissement, Biocodex and Seventure Partners who have committed themselves to subscribe for a total amount of 鈧�14.3m in the Global Offering, subject to the Reserved Offering representing at least 鈧�17 million.

Excluding the proceeds of the Reserved Offering, on the basis of planned expenditure, total cash and cash equivalents as of March 31, 2024, of 鈧�18.2 million (unaudited), the Company estimates that it will be able to fund its operations until the end of September 2024. On the same basis, including the proceeds of the Reserved Offering representing more than 鈧�17 million, the Company estimates that it will be able to finance its operations into early Q1 2025. The Company is also engaged to seek further financing dilutive and/or non-dilutive financing solutions to finance operations beyond early Q1 2025 and remains confident in extending its cash runway to meet its financial obligations over the next 12 months.听 The Company reports in parallel revenues of EUR 0.8 million for the first quarter of 2024 compared with EUR 0.7 million for the same period of 2023, in relation to its Early Access Program for MaaT013 in Europe.

Concurrently with the Primary Offering, certain funds managed by Seventure Partners (together, the 鈥�Selling Shareholder鈥�) will sell a maximum of 125,000 shares, representing a maximum amount of 1 million euros (the 鈥�Secondary Offering鈥� and together with the Primary Offering, the 鈥�Global Offering鈥�). These funds are currently in a divestment period and are progressively selling the shares they hold in the Company, but Seventure Partners will continue to support the development and growth of the Company and has committed to participate to the Reserved Offering through other funds.

Herv茅 Affagard, CEO and co-founder of 黑料社, commented: 鈥�We are pleased to announce a capital increase at a price of 鈧�8 per share with 鈧�14,4 million already committed by our longstanding investors and management. While anchored around our historical investors, this offering is strategically aimed at continuing expanding our shareholder base through retail investors, further increasing our market float. Thus, we have partnered with the PrimaryBid platform to offer them the opportunity to join us under the same conditions as institutional investors.

This transaction will enable us to finalize and present the primary endpoint of the Phase 3 trial of our lead product, MaaT013, in acute graft-versus-host disease, and to support the increase of maturity of our pipeline, including the expansion in the US.听

Encouraged by the positive clinical data from our recent early access program, we are highly motivated to push forward in our development efforts. We are dedicated to a structured approach that aims to bring innovative therapeutic solutions to patients who are battling diseases with limited treatment options and challenging prognoses.鈥�

Terms and Conditions of the Global Offering

The Global Offering will be carried out in three concomitant components under the same pricing conditions:

• a reserved offering (the 鈥�Reserved Offering鈥�) of new ordinary shares without pre-emptive subscription rights, to specific categories of investors, namely: (i) natural person(s) or legal entity(ies), including companies, trusts, investment funds or other investment vehicles, in any form, established under French or foreign law, that regularly invest in the pharmaceutical, biotechnological or medical technologies sectors, as the case may be, when an industrial, commercial, licensing, research or partnership agreement is entered into with the Company; and/or (ii) company(ies), institution(s) or entity(ies) in any form, French or foreign, which conduct a significant portion of their business in these sectors or in the field of cosmetics or chemicals or medical devices or research in these fields, or having entered into an industrial commercial, licensing, research or partnership agreement with the Company, in accordance with the 25^th resolution of the annual general meeting of June 19, 2023 (the 鈥�AGM鈥�) and pursuant to article L. 225-138 of the French Commercial Code
• a public offering of new ordinary shares, aimed at retail investors via the PrimaryBid platform, which will be carried out via an allocation proportional to demand, limited to the amount allocated to this public offering, with allocations reduced should demand exceed this limit, in accordance with the 23^rd resolution of the AGM and pursuant to article L. 225-136 of the French Commercial Code and article L. 411-2-1 1掳 of the French Monetary and Financial Code (the 鈥�PrimaryBid Offering鈥�) , and
• a sale of up to 125,000 existing ordinary shares representing a maximum amount of 1 Million euros held by the Selling Shareholder to the same specific categories of investors defined in the Reserved Offering.

The total amount of the Global Offering would be approximately 18 million euros, with a possibility to increase this total amount, subject to investor demand.

The amount of the Global Offering will depend exclusively on the orders received for each of the above-mentioned components, with no possibility of reallocating the amounts committed to the Reserved Offering and the Secondary Offering, to the PrimaryBid Offering. The PrimaryBid Offering to retail investors is incidental to the Reserved Offering and may not exceed 20% of the total amount of the Global Offering. In any event, the PrimaryBid Offering will not be carried out if the Reserved Offering does not occur.

The Offering Price of the new shares will be at a price of 鈧�8 per share, representing an approximate discount of 15% of the Company鈥檚 shares on the Euronext Paris regulated market at the time of the last trading session preceding announcement (i.e. May 13, 2024), in compliance with the 25th,^听23rd and 27th resolutions of the Company. The Offering Price of the new ordinary shares issued under the PrimaryBid Offering and of the existing shares sold in the Secondary Offering will be equal to the price of the new ordinary shares issued under the Reserved Offering.

The Reserved Offering and the Secondary Offering will be carried out by “accelerated bookbuilding”, at the end of which the number of new shares to be issued and the price per share will be determined by the Chief Executive Officer of the Company, pursuant to and within the limits of the sub-delegations of au thority granted by the Board of Directors of the Company as of the date of this press release and in accordance with the resolutions of the AGM.

The accelerated book-building process for the Reserved Offering and the Secondary Offering will be initiated immediately following the publication of this press release and is expected to close before markets open tomorrow, subject to early closing. The PrimaryBid Offering will also begin immediately and is expected to close at 10 p.m. today, subject to early closing. The Company will announce the results of the Global Offering by press release after the order book closes, tomorrow before the market opens.

The Reserved Offering will be available, within the categories of investors defined above, (i) to institutional investors in France, outside France with the exception of the United States, Canada, Australia and Japan and, solely within the categories of investors specifically provided for in the 25th resolution mentioned above, and (ii) to certain institutional investors in the United States.

Settlement-delivery of the new ordinary shares and their admission to trading on the regulated market of Euronext Paris are expected to occur on May 17, 2024. The new shares will be of the same class and fungible with the existing shares, will carry all rights attached to the shares, and will be admitted to trading on the Euronext Paris market under the same ISIN code FR0012634822 – MAAT.

Shareholders鈥� subscription and lock-up agreements

Current shareholders Bpifrance Investissement, Biocodex and Seventure Partners which hold 15,51%, 10,62% and 22,31% of the Company鈥檚 share capital, respectively on a non-dilutive basis, have pledged to subscribe 鈧�8 million, 鈧�5 million and 鈧�1.3 million respectively in the Reserved Offering, subject for the Reserved Offering representing at least 鈧�17 million. The Management of the Company has pledged to subscribe 鈧�100,000 in the Reserved Offering.

The subscription commitments received by the Company, as detailed above, thus represent a total of 鈧�14.4 million.

The press release announcing the results of the Global Offering will set out the shareholding resulting from the transaction.

The independent directors of the Company were called upon to vote alone on the transaction, unanimously approved both the principle of the transaction and its terms. Mr. Herv茅 Affagard, Mrs Isabelle de Cr茅moux for Seventure Partners, and Mr. Jean-Marie Lef猫vre for Biocodex, did not take part in the vote of this decision.

In connection with the Reserved Offering, participating Directors and certain existing shareholders namely, Seventure Partners, Biocodex and Bpifrance Investissement have respectively entered into a lock-up agreement with the Placement Agent for a period ending 90 days after the settlement and delivery date of the Offering, subject to customary exceptions. In connection with the Reserved Offering, the Company has undertaken to refrain from issuing shares for a period of 90 days from the settlement-delivery date of the Offer, subject to customary exceptions.

Financial Intermediaries

Stifel Europe AG (鈥�Stifel鈥�) are acting as Global Coordinator and Joint Bookrunner in connection with the Reserved Offering. Gilbert Dupont SNC, Groupe Soci茅t茅 G茅n茅rale, is acting as Joint Bookrunner in connection with the Reserved Offering. Stifel is also acting as Centralizing Agent (together, the 鈥�Placement Agents鈥�). The Reserved Offering is subject to a placement agreement entered into between the Company and the Placement Agents dated May 14, 2024.

Within the framework of the PrimaryBid Offering, investors may only subscribe via the PrimaryBid Partners mentioned on the PrimaryBid website. The PrimaryBid Offering is subject to an engagement letter entered into between the Company and PrimaryBid and is not subject to a placement agreement.

Prospectus

In connection with the Reserved Offering, a listing prospectus will be submitted to the Autorit茅 des March茅s Financiers (the “AMF“) prior to the settlement and delivery of the new ordinary shares (the “Prospectus“). The Prospectus will consist of (i) the Company’s universal registration document filed with the AMF on April 2, 2024, under number D.24-0225, with its amendment to be filed with the AMF, and (ii) a securities note including the summary of the Prospectus. This Prospectus will be available on the AMF’s website (www.amf-france.org) and on the Company’s website (www.maatpharma.com/) and may be obtained free of charge from the Company’s registered office.

This press release does not constitute a prospectus under Regulation (EU) 2017/1129 of the European Parliament and of the Council of June 14, 2017, as amended, or a public offering.

Risk factors

The public’s attention is drawn to the risk factors relating to the Company and its business, presented in chapter 3 of the universal registration document 2024 approved by the Autorit茅 des march茅s financiers on April 02, 2024, which is available free of charge on the Company’s website (www.maatpharma.com) and the website of the Autorit茅 des march茅s financiers (www.amf-france.org). The occurrence of any or all of these risks could have an adverse effect on the Company’s business, financial situation, results, development or prospects.

In addition, investors are invited to consider the following risks specific to the issue: (i) the market price of the Company’s shares could fluctuate and fall below the Offering Price of the shares issued under the Offer, (ii) the volatility and liquidity of the Company’s shares could fluctuate significantly, (iii) sales of the Company’s shares could occur on the market and have an unfavorable impact on the Company’s share price, and (iv) the Company’s shareholders could suffer potentially significant dilution as a result of any future capital increases made necessary by the Company’s search for financing.About 黑料社

黑料社, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, 黑料社 has launched, in March 2022, an open-label, single arm Phase 3 clinical trial in patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint庐, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company鈥檚 Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. 黑料社 benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. 黑料社 is listed on Euronext Paris (ticker: MAAT).

Forward-looking Statements

All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company鈥檚 control. These statements may include, without limitation, any statements preceded by, followed by or including words such as 鈥渢arget,鈥� 鈥渂elieve,鈥� 鈥渆xpect,鈥� 鈥渁im,鈥� 鈥渋ntend,鈥� 鈥渕ay,鈥� 鈥渁nticipate,鈥� 鈥渆stimate,鈥� 鈥減lan,鈥� 鈥減roject,鈥� 鈥渨ill,鈥� 鈥渃an have,鈥� 鈥渓ikely,鈥� 鈥渟hould,鈥� 鈥渨ould,鈥� 鈥渃ould鈥� and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company鈥檚 control that could cause the Company鈥檚 actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.

Disclaimer

This press release does not constitute an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of shares in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The distribution of this document may, in certain jurisdictions, be restricted by local legislations. Persons into whose possession this document comes are required to inform themselves about and to observe any such potential local restrictions.

This press release is an advertisement and not a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (as amended, the 鈥�Prospectus Regulation鈥�). Any decision to purchase shares must be made solely on the basis of publicly available information on the Company.

In France, the offer of 黑料社 shares described below will be made in the context of (i) a capital increase reserved to specified categories of beneficiaries, pursuant to article L. 225-138 of the French Commercial Code and applicable regulatory provisions and (ii) a public offering primarily intended to retail investors through the PrimaryBid platform, pursuant to article L. 225-136 of the French Commercial Code and article L.411-2-1, 1掳 of the French Monetary and Financial Code. Pursuant to article 211-3 of the General regulations of the French financial markets authority (Autorit茅 des march茅s financiers) (the “AMF“) and articles 1(4) and 3 of the Prospectus Regulation, the offer of 黑料社 shares will not require the publication of a prospectus approved by the AMF.

With respect to Member States of the European Economic Area, no action has been taken or will be taken to permit a public offering of the securities referred to in this press release requiring the publication of a prospectus in any Member State. Therefore, such securities may not be and shall not be offered in any Member State other than in accordance with the exemptions of Article 1(4) of Prospectus Regulation or, otherwise, in cases not requiring the publication of a prospectus under Article 3 of the Prospectus Regulation and/or the applicable regulations in such Member State.

This press release and the information it contains are being distributed to and are only intended for persons who are (x) outside the United Kingdom or (y) in the United Kingdom and are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the 鈥�Order鈥�), (ii) high net worth entities and other such persons falling within Article 49(2)(a) to (d) of the Order (鈥渉igh net worth companies鈥�, 鈥渦nincorporated associations鈥�, etc.) or (iii) other persons to whom an invitation or inducement to participate in investment activity (within the meaning of Section 21 of the Financial Services and Market Act 2000) may otherwise lawfully be communicated or caused to be communicated (all such persons in (y)(i), (y)(ii) and (y)(iii) together being referred to as 鈥�Relevant Persons鈥�). Any invitation, offer or agreement to subscribe, purchase or otherwise acquire securities to which this press release relates will only be engaged with Relevant Persons. Any person who is not a Relevant Person should not act or rely on this press release or any of its contents.

This press release may not be distributed, directly or indirectly, in or into the United States. This press release and the information contained therein does not, and will not, constitute an offer of securities for sale, nor the solicitation of an offer to purchase, securities in the United States or any other jurisdiction where restrictions may apply. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the 鈥淪ecurities Act鈥�). The securities of 黑料社 have not been and will not be registered under the Securities Act, and 黑料社 does not intend to conduct a public offering in the United States.

A listing prospectus will be submitted to the Autorit茅 des March茅s Financiers (the “AMF”) prior to the settlement and delivery of the new ordinary shares (the “Prospectus”). The Prospectus will consist of (i) the Company’s universal registration document filed with the AMF on April 2, 2024 under number D.24-0225, with its amendment to be filed with the AMF, and (ii) a securities note including the summary of the Prospectus. This Prospectus will be available on the AMF’s website (www.amf-france.org) and on the Company’s website (www.maatpharma.com/) and may be obtained free of charge from the Company’s registered office.

MIFID II Product Governance/Target Market: solely for the purposes of the requirements of article 9.8 of the EU Delegated Directive 2017/593 relating to the product approval process, the target market assessment in respect of the shares of 黑料社 has led to the conclusion in relation to the type of clients criteria only that: (i) the type of clients to whom the shares are targeted is eligible counterparties and professional clients and retail clients, each as defined in Directive 2014/65/EU, as amended (鈥�MiFID II鈥�); and (ii) all channels for distribution of the shares of 黑料社 to eligible counterparties and professional clients and retail clients are appropriate. Any person subsequently offering, selling or recommending the shares of 黑料社 (a 鈥渄istributor鈥�) should take into consideration the type of clients assessment; however, a distributor subject to MiFID II is responsible for undertaking its own target market assessment in respect of the shares of 黑料社 and determining appropriate distribution channels.

The distribution of this press release may be subject to legal or regulatory restrictions in certain jurisdictions. Any person who comes into possession of this press release must inform him or herself of and comply with any such restrictions.

Any decision to subscribe for or purchase the shares or other securities of 黑料社 must be made solely based on information publicly available about 黑料社. Such information is not the responsibility of Stifel and Gilbert Dupont and has not been independently verified by Stifel and Gilbert Dupont.

The post May 14, 2024: 黑料社 Launches a Global Offering of approximately 18 Million Euros appeared first on 黑料社.

Lyon, France, May 7 2024 鈥�6.30 pm CET 鈥� 黑料社 (EURONEXT: MAAT 鈥� the 鈥淐ompany鈥�), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem Therapies^TM (MET) dedicated to improving survival outcomes for patients with cancer,today provided a business update and highlights its key milestones for 2024.

Herv茅 Affagard, CEO and co-founder of 黑料社 said: 鈥淲e’re confidently advancing towards Phase 3 results for MaaT013, meeting milestones and delivering value for shareholders. Recent data at the EBMT annual congress underscores MaaT013’s potential in aGvHD where therapeutic options are insufficient. We are also thrilled to partner with Institut Gustave Roussy (IGR), a world-renowned center in cancer treatment to explore MaaT033’s impact on immune checkpoint inhibitors鈥� response in non-small cell lung cancer patients, and therefore deepening our development in immuno-oncology. This collaboration further strengthens 黑料社鈥檚 leading position in oncology and the medical community鈥檚 interest in microbiome drug candidates.鈥�

听Pipeline highlights

MET-N

MaaT013

• In hemato-oncology:
  • In March 2024, the Company announced the launch of a retrospective multicenter trial called CHRONOS in Europe. Its objective is to provide the Company efficacy data for 3rd-line therapies for patients not receiving MaaT013 or any microbiome intervention. This study was not requested by regulatory authorities and does not impact cash projections as funding has already been secured.
  • In April 2024, at the 50^th annual meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Company presented positive efficacy and safety results in 140 patients treated with MaaT013 in acute graft-versus-host disease (aGvHD) as part of the Early Access Program (EAP). The data presented demonstrates a clear reduction in disease burden and an improved Overall Survival (OS), and highlighted MaaT013’s good safety profile. The results in the 49-patient 鈥淎RES-like鈥� subgroup, with the same characteristics as those of the Phase 3 ARES trial (NCT04769895) demonstrated 63% GI-ORR at D28 and Overall Survival (OS) of 49% at one year and 42% at 18 months. This represents a significant increase when compared with the historical data published by Abedin et al. (used by the medical community as the most recent reference) which showed a limited 15% OS at one year in a similar population.
  • Primary endpoint readout, GI-ORR at D28, of the ARES Phase 3 clinical trial in aGvHD is expected for mid Q4-2024.

• In immuno-oncology:
  • In March 2024, the Company informed on the completion of patient recruitment for the Phase 2a clinical trial PICASSO (NCT04988841) sponsored by AP-HP and in collaboration with INRAE and Institut Gustave Roussy, evaluating MaaT013 in combination with Immune Checkpoint Inhibitors (ICI). Topline results expected in Q4 2024/Q1 2025.

MaaT033

• In immuno-oncology:
  • 黑料社 announces its participation in the IMMUNOLIFE RHU[1] program, a consortium including academic partners, such as Institut Gustave Roussy (IGR), a world-renowned center in the field of cancer treatment, and biotech companies. IMMUNOLIFE aims to solve the significant problem of primary resistance to immune checkpoint inhibitors (ICI) observed in advanced non-small cell lung cancer (NSCLC) patients following antibiotic uptake. MaaT033, an oral, pooled fecal microbiotherapy, developed by 黑料社 will be tested as a concomitant treatment to anti-PD1 therapy to increase the ICI response rate in this Phase 2 randomized multicenter clinical trial including advanced NSCLC patients. Participation in this programwill also grant access to clinical and metagenomic data from听a large cohort of cancer patients (bladder, lung and renal) which will be used to improve 黑料社鈥檚 artificial intelligence (AI) gutPrint庐 platform. The related costs for 黑料社 are limited to clinical product supply in line with previous cash projections.

• In neurodegenerative diseases:
  • In February 2024, the Company announced that the Data Safety and Monitoring Board (DSMB) reviewed safety data in the first 8 patients with Amyotrophic Lateral Sclerosis (ALS) treated with MaaT033 in the Phase 1 clinical trial IASO (). The DSMB, composed of 4 independent experts, including an ALS patient association representative, concluded that safety was good and recommended that the trial continue without modifications.
  • 黑料社 announces the completion of patient recruitment for IASO.

MET-C

MaaT034

• In immuno-oncology:
  • In April 2024, at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, California, the Company presented characterizing the metabolites produced by MaaT034 and their impact on immune modulation. MaaT034 may be the first full-co-cultivated ecosystem therapy for immuno-oncology, combining a diverse array of supportive species with functional networks of interest to improve the response to immune checkpoint inhibitors. The results demonstrate that MaaT034 produced key metabolites, recognized as promoting gut barrier restoration and modulating immune responses. This represents a significant advancement in understanding the mechanism of action (MoA) of co-cultured microbiome therapies developed by 黑料社 marking a major step towards clinical evaluation.

Corporate update

• In March 2024, the Company announced the appointment of Jonathan Chriqui, PharmD, as Chief Business Officer and member of the executive management team. Jonathan will be responsible for 黑料社鈥檚 business development and partnering strategies, increasing the Company鈥檚 ability to secure partnership deals, in line with its strategic objectives.
• 黑料社 has engaged in active discussions with prominent US clinicians in the field of stem cell transplantation to explore the most efficient path forward to introduce MaaT013 to patients in the United States. The Company is pleased to announce the production of batches of MaaT013 destined for clinical supply in the US as the Company pursues the readiness phase in advance of clinical study initiation.
• The Company believes it has sufficient cash to finance operations to the end of Q3 2024. While the Company does not have sufficient cash to finance its operations for the next twelve months, it has active ongoing discussions to finance operations beyond the end of Q3 2024 and remains confident in extending its cash runway.

Key value creation milestones in 2024

• MaaT013
  • Mid-Q4: Primary endpoint readout (GI-ORR at D28) from the ARES Phase 3 clinical trial in aGvHD
  • Q4 2024/Q1 2025: Topline results of the PICASSO Phase 2a clinical trial in metastatic melanoma
• MaaT033
  • H2 2024: First DSMB^[2] of the PHOEBUS Phase 2b clinical trial in allo-HSCT
  • H2 2024: Results of the IASO Phase 1 clinical trial in ALS
• MaaT034
  • H1 2024: Candidate selection
  • H2 2024: Start of the production of the first cGMP batch

Upcoming investor and business conferences participation

• June 3-6, 2024 鈥� BIO 2024
• June 11-12, 2024 鈥� Portzamparc Mid & Small Caps 2024 Conference
• June 25-27, 2024 鈥� Stifel European Healthcare Summit Lyon
• July 10-12, 2024 鈥� Microbiome Movement Drug Development Summit

听

[1] Contract N掳 ANR-21-RHUS-0017 鈥� RHU stands for Recherche Hospitalo-Universitaire – University Hospital Research

[2] at the recruitment of 60 patients

About 黑料社

黑料社, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, 黑料社 has launched, in March 2022, an open-label, single arm Phase 3 clinical trial in patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint庐, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company鈥檚 Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. 黑料社 benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. 黑料社 is listed on Euronext Paris (ticker: MAAT).

Forward-looking Statements

All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company鈥檚 control. These statements may include, without limitation, any statements preceded by, followed by or including words such as 鈥渢arget,鈥� 鈥渂elieve,鈥� 鈥渆xpect,鈥� 鈥渁im,鈥� 鈥渋ntend,鈥� 鈥渕ay,鈥� 鈥渁nticipate,鈥� 鈥渆stimate,鈥� 鈥減lan,鈥� 鈥減roject,鈥� 鈥渨ill,鈥� 鈥渃an have,鈥� 鈥渓ikely,鈥� 鈥渟hould,鈥� 鈥渨ould,鈥� 鈥渃ould鈥� and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company鈥檚 control that could cause the Company鈥檚 actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.

The post May 7, 2024: 黑料社 Provides a Business Update and Highlights Key Milestones Expected in 2024 appeared first on 黑料社.

Lyon, France, April 5 2024 鈥�7.30 am CET 鈥� 黑料社 (EURONEXT: MAAT 鈥� the 鈥淐ompany鈥�), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem Therapies^TM (MET) dedicated to improving survival outcomes for patients with cancer, announces the initiation of coverage of its stock by Gilbert Dupont.

With a research report named 鈥淓chec et MaaT鈥�, Gilbert Dupont / Groupe Soci茅t茅 G茅n茅rale initiated coverage of 黑料社 on April 4^th, 2024 with a Buy recommendation and a Target Price of 16 Euros.

This new coverage strengthens the visibility of 黑料社 among French and international institutional investors and adds to the ongoing coverage by the brokerage firms, Kepler Cheuvreux, KBC Securities, Kempen and Portzamparc/Groupe BNP Paribas.

About 黑料社

黑料社, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, 黑料社 has launched, in March 2022, an open-label, single arm Phase 3 clinical trial in patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint庐, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company鈥檚 Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. 黑料社 benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. 黑料社 is listed on Euronext Paris (ticker: MAAT).

Forward-looking Statements

All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company鈥檚 control. These statements may include, without limitation, any statements preceded by, followed by or including words such as 鈥渢arget,鈥� 鈥渂elieve,鈥� 鈥渆xpect,鈥� 鈥渁im,鈥� 鈥渋ntend,鈥� 鈥渕ay,鈥� 鈥渁nticipate,鈥� 鈥渆stimate,鈥� 鈥減lan,鈥� 鈥減roject,鈥� 鈥渨ill,鈥� 鈥渃an have,鈥� 鈥渓ikely,鈥� 鈥渟hould,鈥� 鈥渨ould,鈥� 鈥渃ould鈥� and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company鈥檚 control that could cause the Company鈥檚 actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.

The post April 5, 2024: 黑料社 Announces Initiation of Coverage of its Stock by Gilbert Dupont/ Groupe Soci茅t茅 G茅n茅rale appeared first on 黑料社.

Lyon, France, March 21, 2024 鈥�6.00pm CET 鈥� 黑料社 (EURONEXT: MAAT 鈥� the 鈥淐ompany鈥�), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem Therapies^TM (MET) dedicated to improving survival outcomes for patients with cancer, today announced the appointment of Jonathan Chriqui, PharmD, as Chief Business Officer and member of the executive management team. Jonathan Chriqui will be responsible for 黑料社鈥檚 business development and partnering strategies along with promoting 黑料社’s innovations within the microbiome industry.

鈥淲e are very pleased to welcome Jonathan at this pivotal time for 黑料社. Jonathan鈥檚 expertise and extensive experience will be instrumental in securing strategic partnerships and maximizing the potential of our pipeline. 黑料社 is now poised to propel its lead asset, MaaT013, into the next phase of development and prepare for its commercial launch,鈥� said Herv茅 Affagard, Chief Executive Officer and co-founder of 黑料社.

Jonathan brings over 15 years of business development experience working at Ipsen and Servier, including leadership in strategic transactions in the field of microbiota as well as collaborations, licensing, M&A, and alliance management. Previously, he held the role of Chief Operating & Chief Business Development Officer at Somagenetix in Zurich, Switzerland, which is developing gene therapies for rare diseases in immunology, neurology, and oncology.

鈥淭he gut microbiome as a therapeutic modality holds the potential to transform cancer treatment, and I’m thrilled to join 黑料社. My goal is to support the growth of the company, which is recognized worldwide for its technology leadership and innovative approach towards oncology indications. I look forward to contributing to the advancement of MaaT013 towards the market and supporting the company鈥檚 mission of providing new treatment options for patients with cancer,鈥� shared Jonathan Chriqui, Chief Business Officer at 黑料社.

About 黑料社

黑料社, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, 黑料社 has launched, in March 2022, an open-label, single arm Phase 3 clinical trial in patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint庐, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company鈥檚 Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. 黑料社 benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. 黑料社 is listed on Euronext Paris (ticker: MAAT).

Forward-looking Statements

All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company鈥檚 control. These statements may include, without limitation, any statements preceded by, followed by or including words such as 鈥渢arget,鈥� 鈥渂elieve,鈥� 鈥渆xpect,鈥� 鈥渁im,鈥� 鈥渋ntend,鈥� 鈥渕ay,鈥� 鈥渁nticipate,鈥� 鈥渆stimate,鈥� 鈥減lan,鈥� 鈥減roject,鈥� 鈥渨ill,鈥� 鈥渃an have,鈥� 鈥渓ikely,鈥� 鈥渟hould,鈥� 鈥渨ould,鈥� 鈥渃ould鈥� and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company鈥檚 control that could cause the Company鈥檚 actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.

The post March 21, 2024: 黑料社 Strengthens Executive Team Appointing Jonathan Chriqui as Chief Business Officer appeared first on 黑料社.